EMERALD MUTUAL FUND ADVISERS TRUST recently filed their 13F report for the fourth quarter of 2022, which ended on 2022-12-31.
The 13F report details which stocks were in a guru’s equity portfolio at the end of the quarter, though investors should note that these filings are limited in scope, containing only a snapshot of long positions in U.S.-listed stocks and American depository receipts as of the quarter’s end. They are not required to include international holdings, short positions or other types of investments. Still, even this limited filing can provide valuable information.
3175 Oregon Pike Leola, PA 17540
As of the latest 13F report, the guru’s equity portfolio contained 218 stocks valued at a total of $1.61Bil. The top holdings were SMPL(1.97%), SMCI(1.94%), and MTSI(1.84%).
According to GuruFocus data, these were EMERALD MUTUAL FUND ADVISERS TRUST’s top five trades of the quarter.
Insmed Inc
The guru established a new position worth 747,146 shares in NAS:INSM, giving the stock a 0.93% weight in the equity portfolio. Shares traded for an average price of $19.33 during the quarter.
On 02/04/2023, Insmed Inc traded for a price of $21.59 per share and a market cap of $2.92Bil. The stock has returned -0.46% over the past year.
GuruFocus gives the company a financial strength rating of 2 out of 10 and a profitability rating of 1 out of 10.
In terms of valuation, Insmed Inc has a EV-to-Ebitda ratio of -8.05 and a price-sales ratio of 10.69.
The price-to-GF Value ratio is 0.63, earning the stock a GF Value rank of 8.
Integer Holdings Corp
EMERALD MUTUAL FUND ADVISERS TRUST reduced their investment in NYSE:ITGR by 218,255 shares. The trade had a 0.86% impact on the equity portfolio. During the quarter, the stock traded for an average price of $65.36.
On 02/04/2023, Integer Holdings Corp traded for a price of $73.5 per share and a market cap of $2.44Bil. The stock has returned -5.98% over the past year.
GuruFocus gives the company a financial strength rating of 4 out of 10 and a profitability rating of 6 out of 10.
In terms of valuation, Integer Holdings Corp has a price-earnings ratio of 34.19, a price-book ratio of 1.80, a EV-to-Ebitda ratio of 17.48 and a price-sales ratio of 1.81.
The price-to-GF Value ratio is 0.85, earning the stock a GF Value rank of 9.
Silvergate Capital Corp
The guru sold out of their 177,972-share investment in NYSE:SI. Previously, the stock had a 0.85% weight in the equity portfolio. Shares traded for an average price of $39.67 during the quarter.
On 02/04/2023, Silvergate Capital Corp traded for a price of $18.83 per share and a market cap of $596.14Mil. The stock has returned -81.55% over the past year.
GuruFocus gives the company a financial strength rating of 4 out of 10 and a profitability rating of 5 out of 10.
In terms of valuation, Silvergate Capital Corp has a price-book ratio of 0.99.
The price-to-GF Value ratio is 0.20, earning the stock a GF Value rank of 2.
ChampionX Corp
The guru established a new position worth 462,478 shares in NAS:CHX, giving the stock a 0.83% weight in the equity portfolio. Shares traded for an average price of $27.6 during the quarter.
On 02/04/2023, ChampionX Corp traded for a price of $29.17 per share and a market cap of $5.82Bil. The stock has returned 27.36% over the past year.
GuruFocus gives the company a financial strength rating of 6 out of 10 and a profitability rating of 6 out of 10.
In terms of valuation, ChampionX Corp has a price-earnings ratio of 38.89, a price-book ratio of 3.43, a EV-to-Ebitda ratio of 12.94 and a price-sales ratio of 1.51.
The price-to-GF Value ratio is 1.08, earning the stock a GF Value rank of 3.
Prometheus Biosciences Inc
The guru established a new position worth 120,745 shares in NAS:RXDX, giving the stock a 0.82% weight in the equity portfolio. Shares traded for an average price of $64.84999999999999 during the quarter.
On 02/04/2023, Prometheus Biosciences Inc traded for a price of $108.68 per share and a market cap of $5.05Bil. The stock has returned 207.96% over the past year.
GuruFocus gives the company a financial strength rating of 6 out of 10 and a profitability rating of 1 out of 10.
In terms of valuation, Prometheus Biosciences Inc has a price-book ratio of 19.55, a EV-to-Ebitda ratio of -36.39 and a price-sales ratio of 590.09.
Please note, the numbers and facts quoted are as of the writing of this article and may not factor in the latest trading data or company announcements.
When GuruFocus covers insider information, we only track open market or the private purchase and sale of common stock with the transaction code of P or S. Therefore, all the transactions mentioned in this article are only the ones with transaction code of P or S.
Want to provide feedback on this article? Have questions or concerns? Get in touch with us here, or email us at [email protected]!
This article is general in nature and does not represent the opinions of GuruFocus or any of its affiliates. This article is not intended to be financial advice, nor does it constitute investment advice or recommendations. It was written without regard to your individual situation or financial goals. We aim to bring you fundamental, data-driven analysis, The information on this site is in no way guaranteed for completeness, accuracy or in any other way.
